DV
Dividend Vision

SPTX — Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. (SPTX)

Total return is 242100.0% over the past 0.4 years, 242081.2 points ahead of SPY at 18.8%.

Seaport Therapeutics is a clinical-stage biopharmaceutical company developing novel oral treatments for depression, anxiety, and other neuropsychiatric disorders using its proprietary Glyph platform; its lead candidates are GlyphAllo for postpartum depression and GlyphAgo for anxiety and depression. The company does not currently distribute dividends. Seaport Therapeutics appeals to investors seeking exposure to early-stage drug development with potential upside, though the company is pre-revenue and carries the risks typical of clinical-stage biotechnology.

SPTX key facts

Asset type
Stock
Asset class
Equity
Inception date
03/23/2026
Distribution frequency
None
Last close
$24.22
Market cap
$1,296,509,952
Average volume
121100.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.55